Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118424 | 0.84 | PPARA (0.51) | NPC1RAB9ASMN1; SMN2PPARAPPARG | |
| SCHEMBL3998978 | 0.81 | PPARA (0.56) | PPARAPPARGPPARD | |
| SCHEMBL6714997 | 0.81 | PPARA (0.58) | GAAPPARAPPARGPPARD | |
| SCHEMBL6713621 | 0.80 | PPARA (0.57) | PPARALTA4HPPARGPPARD | |
| SCHEMBL2807182 | 0.78 | PPARG (0.55) | ALDH1A1GAAKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL6722312 | 0.77 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL3996490 | 0.77 | OPRK1 (0.51) | ALDH1A1SMN1; SMN2PPARALTA4HPPARG | |
| SCHEMBL14176244 | 0.76 | LMNA (0.54) | ALDH1A1KDM4EPPARAPPARGPPARD | |
| SCHEMBL5213397 | 0.75 | PPARG (0.52) | ALDH1A1GAAKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL2804981 | 0.75 | OPRK1 (0.51) | ALDH1A1PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474385-B1 | UREA LINKER DERIVATIVES FOR USE AS PPAR MODULATORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-6984661-B2 | Urea linker derivatives for use as PPAR modulators | ELI LILLY AND COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050004183-A1 | for preventing, Syndrome X, diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases; peroxisome proliferator activated receptor (PPAR) | ELI LILLY AND COMPANY | 2005-01-06 | — | — | US | disclosed |
| EP-1474385-A1 | UREA LINKER DERIVATIVES FOR USE AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003066581-A1 | UREA LINKER DERIVATIVES FOR USE AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004183-A1 | for preventing, Syndrome X, diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases; peroxisome proliferator activated receptor (PPAR) | PPARA, GPR119, PPARD | ALDH1A1 1454/4885GAA 3152/4885KDM4E 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.